Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.65 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 4/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL9013957 | 0.97 | AGTR2 (0.69) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| Angiotensin Ii SCHEMBL22125774 | 0.97 | AGTR2 (0.69) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| Angiotensin Ii SCHEMBL9013950 | 0.97 | AGTR2 (0.69) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL30445863 | 0.97 | AGTR2 (0.69) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| Angiotensin Ii SCHEMBL29757879 | 0.97 | AGTR2 (0.69) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL29972916 | 0.96 | AGTR1 (0.62) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| Angiotensin Ii SCHEMBL28966994 | 0.96 | AGTR2 (0.68) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| Angiotensin Ii SCHEMBL30960106 | 0.96 | AGTR2 (0.68) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| Angiotensin-Ii SCHEMBL29973063 | 0.96 | AGTR2 (0.62) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL24454648 | 0.95 | AGTR2 (0.69) | AGTR2AGTR1C5AR1NTSR1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | disclosed |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-20020160985-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-10-31 | — | — | US | disclosed |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.1.C. | 2002-09-19 | — | — | US | disclosed |
| US-20020086893-A1 | Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2002-07-04 | — | — | US | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010181-A1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010187-A1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010179-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010188-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010182-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010180-A1 | USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160985-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885C5AR1 414/4885 |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, AGT | AGTR2 1/4885AGTR1 2/4885C5AR1 311/4885 |
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885C5AR1 523/4885 |
| US-20020086893-A1 | Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke | AGTR2, AGTR1, VIPR2 | AGTR2 1/4885AGTR1 2/4885C5AR1 978/4885 |
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885C5AR1 187/4885 |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | AGTR1, AGTR2, AGT | AGTR2 2/4885AGTR1 1/4885C5AR1 678/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885C5AR1 523/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885C5AR1 804/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR2 1/4885AGTR1 2/4885C5AR1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.